

AU InforMed

Volume 24 Number 1 (Issue 353)

Friday, January 30, 2026

Guest Editors: Duncan George and Lily Park, Pharm.D. Candidates 2026, Bernie R. Olin, Pharm.D.



Key Inforbits

- 2025 New Drug Approvals
- Disease Categories with New Treatment Options in 2025

New Drugs Approved in 2025

Brand/ Generic (Manufacturer)	Date (2025)	Category	FDA Indication	Route	Warning/Precautions
Andembry/ Garadacimab-gxii (CSL Behring)*	6/16	Activated Factor XII (FXIIa) inhibitor	prevent attacks of hereditary angioedema	SQ	Warnings/Precautions: None Common ADRs: nasopharyngitis and abdominal pain
Anzupgo/ Delgocitinib (Leo)	7/23	Janus kinase (JAK) inhibitor	moderate-to- severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response	TOP	Warnings/Precautions: Serious Infections, Non-melanoma Skin Cancers, Avoid live immunizations, and Potential Risks Related to JAK Inhibition Common ADRs: Mostly well tolerated with some rare but serious ADRs
Avmapki Fakzynja Co-Pack / avutometinib and defactinib (Verastem)*	5/8	Kinase inhibitors	KRAS-mutated recurrent low- grade serous ovarian cancer (LGSOC) after prior systemic therapy	PO	Warnings/Precautions: Dermatologic toxicity, Hepatotoxicity, Ocular toxicity, Rhabdomyolysis, and Embryo-Fetal Toxicity Common ADRs: nausea/vomiting (n/v), rash, diarrhea, musculoskeletal pain, edema, abdominal pain, stomatitis, pruritus, visual impairment, decreased platelets, dyspnea, urinary tract infection, and decreased neutrophil and lymphocyte count.
Blujepa/ Gepotidacin (GlaxoSmithKline)	3/25	Triazaace naphthylene bacterial type II topoisome rase inhibitor	uncomplicated urinary tract infections	PO	Warnings/Precautions: QTc Prolongation, Acetylcholinesterase inhibition, and Clostridioides difficile Infection Common ADRs: diarrhea, nausea, abdominal pain, flatulence, headache, soft feces, dizziness, vomiting, and vulvovaginal candidiasis.

Brand/ Generic (Manufacturer)	Date (2025)	Category	FDA Indication	Route	Warning/Precautions
Brinsupri Brensocatic (Insmed)	8/12	Dipeptidyl peptidase 1 (DPP1) inhibitor	non-cystic fibrosis bronchiectasis	PO	Warnings/Precautions: Dermatologic ADRs, Gingival and Periodontal ADRs, and Live Attenuated Vaccines Common ADRs: upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, hypertension
Cardamyst/ Etripamil (Milestone)	12/12	Calcium channel blocker	episodes of paroxysmal supraventricular tachycardia	NS	Warnings/Precautions: Contraindicated with heart failure II to IV, Wolff- Parkinson-White or Lown-Ganong-Levine syndromes, Sick sinus syndrome, and Second degree atrioventricular (AV) Mobitz 2 block or higher degree of AV block. Syncope Common ADRs: nasal discomfort, nasal congestion, rhinorrhea, throat irritation, and epistaxis
Datroway/ datopotamab deruxtecan-dlnk (Daiichi Sankyo)	1/17	Trop-2- directed antibody and topoisome rase inhibitor	unresectable or metastatic, HR- positive, HER2- negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease	IV	Warnings/Precautions: Ocular Toxicity, Interstitial Lung Disease (ILD) and Pneumonitis, Embryo-Fetal Toxicity, and Stomatitis Common ADRs: stomatitis, n/v, fatigue, decreased leukocytes, decreased calcium, alopecia, decreased lymphocytes, decreased hemoglobin, constipation, decreased neutrophils, dry eye, and keratitis
Dawnzera/ Donidalorsen (Ionis)*	8/21	Prekallikrei n-directed antisense oligonucle otide	prevent attacks of hereditary angioedema	SQ	Warnings/Precautions: None Common ADRs: injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort
Ekterly/ Sebetralstat (Kalvista Therapeutics)*	7/3	Plasma kallikrein inhibitor	acute attacks of hereditary angioedema	PO	Warnings/Precautions: None Common ADRs: headache ($\geq 2\%$)
Emrelis/ telisotuzumab vedotin-tllv (Abbvie)	5/14	c-Met- directed antibody and microtubul e inhibitor	locally advanced or metastatic, non- squamous non- small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy	IV	Warnings/Precautions: Peripheral Neuropathy, ILD/Pneumonitis, Ocular Surface Disorders, Infusion-Related Reactions, and Embryo-Fetal Toxicity Common ADRs: peripheral neuropathy, fatigue, decreased appetite, and peripheral edema

Brand/ Generic (Manufacturer)	Date (2025)	Category	FDA Indication	Route	Warning/Precautions
Enflonsia/ clesrovimab-cfor (Merck Sharp Dohme)	6/9	Respirator y syncytial virus (RSV) F protein- directed fusion inhibitor	prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season	IM	Warnings/Precautions: Hypersensitivity of Enflonsia or other IgG1 monoclonal antibodies Common ADRs: injection-site erythema, injection-site swelling and rash
Exdensur/ Depemokimab-ulaa (GlaxoSmithKline)	12/16	Interleukin -5 (IL-5) antagonist	severe asthma characterized by an eosinophilic phenotype as an add-on maintenance therapy	SQ	Warnings/Precautions: Helminth Infections and abrupt discontinuation of systemic or inhaled corticosteroids Common ADRs: upper respiratory tract infection, allergic rhinitis, influenza, arthralgia, and pharyngitis
Forzinity/ Elamipretide (Stealth BioTheraoetics)*	9/19	Mitochond rial cardiolipin binder	improve muscle strength in patients with Barth syndrome weighing at least 30 kg	SQ	Warnings/Precautions: Benzyl alcohol toxicity Common ADRs: injection site reactions
Gomekii/ Mirdametinib (Springworks)*	2/11	Kinase inhibitor	Neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection	PO	Warnings/Precautions: Ocular Toxicity, Left Ventricular Dysfunction, Dermatologic Adverse Reactions, and Embryo-Fetal Toxicity Common ADRs: rash, diarrhea, nausea, musculoskeletal pain, vomiting, and fatigue.
Grafapex/ Treosulfan (Medexus)*	1/21	Alkylating drug	For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome <u>Drug Trials Snapshot</u>	IV	Warnings/Precautions: Seizures, Skin disorders, Injection Site Reactions and Tissue Necrosis, Secondary Malignancies, Embryo-Fetal toxicity Common ADRs: musculoskeletal pain, stomatitis, pyrexia, n/v, edema, and infection
Hernexeos/ Zongertinib (Boehringer Ingelheim)	8/8	Kinase inhibitor	adults with unresectable or metastatic non- squamous non- small cell lung cancer whose tumors have	PO	Warnings/Precautions: Hepatotoxicity, Left Ventricular Dysfunction, Pneumonitis, and Embryo-Fetal Toxicity Common ADRs: diarrhea, hepatotoxicity, rash, fatigue, and nausea

Brand/ Generic (Manufacturer)	Date (2025)	Category	FDA Indication	Route	Warning/Precautions
			HER2 tyrosine kinase domain activating mutations, and who have received prior systemic therapy		
Hyrnuo/ Sevabertinib (Bayer Healthcare)*	11/19	Kinase inhibitor	locally advanced or metastatic non-squamous non-small cell lung cancer that has activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy	PO	Warnings/Precautions: Diarrhea, Hepatotoxicity, Pneumonitis, Ocular Toxicity, Pancreatic Enzyme Elevation, and Embryo-Fetal Toxicity Common ADRs: diarrhea, rash, paronychia, stomatitis, and nausea.
Ibtrozi/ Tafrectinib (Nuvation)*	6/11	Kinase inhibitor	locally advanced or metastatic ROS1-positive non-small cell lung cancer	PO	Warnings/Precautions: Hepatotoxicity, Pneumonitis, QTc prolongation, Hyperuricemia, Skeletal Fractures, Myalgia with Creatine Phosphokinase Elevation, and Embryo-Fetal Toxicity Common ADRs: diarrhea, n/v, dizziness, rash, constipation, and fatigue
Imaavy/ Nipocalimab-aahu (Janssen)*	4/29	Neonatal Fc receptor blocker	generalized myasthenia gravis	IV	Warnings/Precautions: Infections and Infusion-Related Reactions Common ADRs: respiratory tract infections, peripheral edema, and muscle spasms
Inluriyo/ Imlunestrant (Eli Lilly & Company)	9/25	Estrogen receptor antagonist	estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy	PO	Warnings/Precautions: Embryo-Fetal Toxicity Common ADRs: hemoglobin decreased, musculoskeletal pain, neutrophils decreased, fatigue, diarrhea, nausea, platelets decreased, constipation, , and abdominal pain
Jascayd/ Nerandomilast (Boehringer Ingelheim)*	10/7	Phosphodiesterase 4 (PDE4) inhibitor	idiopathic pulmonary fibrosis	PO	Warnings/Precautions: None Common ADRs: diarrhea, COVID-19, upper respiratory tract infection, depression, weight decreased, decreased appetite, nausea/vomiting, fatigue, headache, back pain, and dizziness.

Brand/ Generic (Manufacturer)	Date (2025)	Category	FDA Indication	Route	Warning/Precautions
Journavx/ Suzetrigine (Vertex Pharmaceuticals)	1/30	Sodium channel blocker	moderate to severe acute pain	PO	Warnings/Precautions: Concomitant use with strong CYP3A inhibitors is contraindicated. Moderate and Severe Hepatic Impairment Common ADRs: pruritus, muscle spasms, increased creatine phosphokinase, and rash
Keytruda Qlex/ pembrolizumab and berahyaluronidase alfa-pmph (Merck & Co)	9/19	Combinati on of pembrolizu mab, a programm ed death receptor-1 (PD-1)- blocking antibody, and berahyalur onidase alfa, an endoglyco sidase	adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab	SQ	Warnings/Precautions: Immune-Mediated ADRs, Infusion-related reactions, Complications of allogeneic HSCT, Multiple Myeloma, and Embryo-Fetal toxicity Common ADRs: fatigue, musculoskeletal pain, rash, diarrhea, pyrexia, cough, decreased appetite, pruritus, dyspnea, constipation, pain, abdominal pain, nausea, and hypothyroidism.
Komzifti/ Ziftomenib (Kyowa Kirin/Kura Oncology)*	11/13	Menin inhibitor	adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options	PO	Warnings/Precautions: QTc Prolongation and Embryo-Fetal Toxicity Common ADRs: infection, hemorrhage, diarrhea, nausea, fatigue, edema, musculoskeletal pain, differentiation syndrome, pruritus, febrile neutropenia, and transaminases increased
Kygevvi/ doxycitine and doxribtimine (UCB)*	11/3	Pyrimidine nucleoside s	thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger	PO	Warnings/Precautions: Elevated Liver Transaminase Levels and Gastrointestinal Adverse Reactions Common ADRs: diarrhea, abdominal pain, vomiting, increased ALT, and increased AST
Lerochol/ Lerodalci bep-liga (LIB therapeutics)	12/12	PCSK9 inhibitor	reduce low-density lipoprotein cholesterol in adults with hypercholesterole mia, including heterozygous familial hypercholesterole mia, as an adjunct to diet/ exercise	SQ	Warnings/Precautions: None Common ADRs: nasopharyngitis and injection site reactions

Brand/ Generic (Manufacturer)	Date (2025)	Category	FDA Indication	Route	Warning/Precautions
Lynkuet/ Elinzanetant (Bayer HealthCare)	10/24	Neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist	moderate-to- severe vasomotor symptoms due to menopause	PO	Warnings/Precautions: CNS Depressant Effect, Hepatic Transaminase Elevations, Risk of pregnancy loss, and Risk of seizures Common ADRs: headache, fatigue, dizziness and somnolence
Lynozytic/ Linvoseltamab- gcpt (Regeneron)*	7/2	Bispecific B-cell maturation antigen (BCMA)	relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulator y agent, and an anti CD38 monoclonal antibody	IV	Warnings/Precautions: Infections, Neutropenia, Hepatotoxicity, and Embryo- Fetal Toxicity Common ADRs: musculoskeletal pain, cytokine release syndrome, cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache, and dyspnea
Modeyso/ Dordaviprone (Chimerix)*	8/6	Protease activator	diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy	PO	Warnings/Precautions: QTc Prolongation and Embryo-fetal Toxicity Common ADRs: fatigue, headache, vomiting, nausea, and musculoskeletal pain
Myqorzo/ Aficamten (Cytokinetics)*	12/19	Cardiac myosin inhibitor	Symptomatic obstructive hypertrophic cardiomyopathy	PO	Warnings/Precautions: Contraindicated with Rifampin. Risk of Heart Failure and Drug Interactions Leading to Increased Risk of Heart Failure or Loss of Effectiveness Common ADRs: hypertension
Nereus/ Tradipitant (Vanda)	12/30	Substance P/neurokin in-1 (NK-1) receptor antagonist	Vomiting associated with motion	PO	Warnings/Precautions: Effects on the Ability to Drive or Operate Machinery Common ADRs: somnolence, headache, and fatigue.
Nuzolvece/ Zoliflodacin (Entasis Therapeutics)	12/12	Spiropyrim idinetrione bacterial type II topoisome rase inhibitor	uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae	PO	Warnings/Precautions: Contraindicated with concomitant use with moderate or strong CYP3A4 inducers. Embryo-Fetal Toxicity, Testicular Toxicity, and Clostridioides difficile Infection Common ADRs: neutropenia, headache, leukopenia, dizziness, nausea, and diarrhea.

Brand/ Generic (Manufacturer)	Date (2025)	Category	FDA Indication	Route	Warning/Precautions
Palsonify/ Paltusotine (Crinetics)*	9/25	Somatostatin receptor agonist	acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option	PO	Warnings/Precautions: Cholelithiasis, Hyperglycemia and Hypoglycemia, Cardiovascular Abnormalities, Thyroid Function Abnormalities, Steatorrhea and Malabsorption of Dietary Fats, and Vitamin B12 Deficiency Common ADRs: diarrhea, abdominal pain, decreased appetite, sinus bradycardia, hyperglycemia, palpitations, and gastroenteritis
penpulimab-kcqx/ Penpulimab-kcqx (Akeso Biopharma)*	4/23	Program- med death receptor-1 (PD-1)- blocking antibody	In combination with cisplatin or carboplatin and gemcitabine, adults with recurrent or metastatic non- keratinizing nasopharyngeal carcinoma (NPC), or a single agent while on/after platinum-based chemotherapy and one other line of therapy	IV	Warnings/Precautions: Immune-Mediated Pneumonitis, Colitis, Endocrinopathies Hepatitis and Hepatotoxicity. Infusion-Related Reactions, and Embryo-Fetal Toxicity Common ADRs: nausea, vomiting, hypothyroidism, constipation, decreased appetite, decreased weight, cough, COVID-19 infection, fatigue, rash, and pyrexia
Qfitlia/ Fitusiran (Genzyme)*	3/28	Antithrom- bin-directed small interfering ribonucleic acid	prevent or reduce the frequency of bleeding episodes in hemophilia A or B	SQ	Warnings/Precautions: Hepatotoxicity Common ADRs: viral infection, nasopharyngitis, and bacterial infection
Redempro/ Plozasiran (Arrowhead)*	11/18	Apolipopro- tein C-III	reduce triglycerides in adults with familial chylomicronemia syndrome	SQ	Warnings/Precautions: None Common ADRs: hyperglycemia, headache, nausea, and injection site reaction
Rhapsido/ Remibrutinib (Novartis)	9/30	Kinase inhibitor	chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment	PO	Warnings/Precautions: Risk of Bleeding and Live Attenuated Vaccines Common ADRs: nasopharyngitis, bleeding, headache, nausea and abdominal pain
Romvimza/ Vimseltinib (Deciphera)	2/14	Kinase inhibitor	symptomatic tenosynovial giant cell tumor and surgical resection will potentially cause worsening functional limitation or severe morbidity	PO	Warnings/Precautions: Hepatotoxicity and Embryo-Fetal Toxicity Common ADRs: periorbital edema, fatigue, rash, increased cholesterol, peripheral edema, face edema, decreased neutrophils, decreased leukocytes, and pruritus

Brand/ Generic (Manufacturer)	Date (2025)	Category	FDA Indication	Route	Warning/Precautions
Sepience/ Sepiapterin (PTC Therapeutics)*	7/28	Phenyl- alanine hydroxy- lase (PAH) activator	hyperphenylalanin emia in patients with sepiapterin- responsive phenylketonuria, with phenylalanine- restricted diet	PO	Warnings/Precautions: Increased Bleeding, Hyperphenylalaninemia, and Interaction with Levodopa Common ADRs: diarrhea, headache, abdominal pain, feces discoloration, and oropharyngeal pain
Tryptyr/ Acoltremon (Alcon Labs)	5/28	TRPM8 thermorec eptor agonist	signs and symptoms of dry eye disease	Eye	Warnings/Precautions: Avoid touching vial tip to the eye or other surfaces to avoid potential injury or contamination Common ADRs: instillation site pain
Vanrafia/ Atrasentan (Novartis)	4/02	Endothelin receptor antagonist	reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid progression	PO	Warnings/Precautions: Contraindicated in pregnancy. Hepatotoxicity, Fluid Retention, and Decreased Sperm Counts Common ADRs: peripheral edema and anemia.
Vizz/ Aceclidine (Lenz Therapeutics)	7/31	Choliner- gic agonist	presbyopia	Eye	Warnings/Precautions: Blurred Vision, Retinal Tear/Detachment, and Iritis Common ADRs: instillation site irritation, dim vision, and headache
Voyxact/ Sibeprenlimab-szsi (Otsuka)	11/25	Prolifera- tion Inducing Ligand (APRIL) blocker	reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression	SQ	Warnings/Precautions: Immunosuppression and Live Attenuated Vaccines Common ADRs: upper respiratory tract infection and injection site erythema
Wayrilz/ Rilzabrutinib (Genzyme)*	8/29	Kinase inhibitor	persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids	PO	Warnings/Precautions: Serious Infections, Hepatotoxicity, and Embryo-Fetal Toxicity Common ADRs: diarrhea, nausea, headache, abdominal pain, and COVID-19
Yartemlea/ Narsoplimab-wuug (Omeros)*	12/23	Mannan- binding lectin- associated serine	hematopoietic stem cell transplant- associated thrombotic microangiopathy	IV	Warnings/Precautions: Serious Infections Common ADRs: viral infections, sepsis, hemorrhage, diarrhea, vomiting, nausea, neutropenia, pyrexia, fatigue and hypokalemia

Brand/ Generic (Manufacturer)	Date (2025)	Category	FDA Indication	Route	Warning/Precautions
		protease-2 (MASP-2) inhibitor			
Zegfrovy/ Sunvozertinib (Dizal Jiangsu)	7/2	Kinase inhibitor	locally advanced or metastatic non- small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum- based chemotherapy	PO	Warnings/Precautions: Pneumonitis, GI ADRs, Dermatologic ADRs, Ocular Toxicity, and Embryo-Fetal Toxicity Common ADRs: diarrhea, rash, decreased appetite, stomatitis, fatigue, nausea, paronychia, constipation, musculoskeletal pain, pruritus, urinary tract infection, abdominal pain and decreased weight

IM: intramuscular IV: intravenous SQ: subcutaneous PO: by mouth
Eye: ophthalmic TOP: topical NS: nasal *: orphan drug

Disease Categories with New Treatment Options in 2025

Infectious Diseases	<ul style="list-style-type: none"> ● Nuzolvence (zoliflodacin) ● Blujepa (gepotidacin) 	<ul style="list-style-type: none"> ● Enflonsia (clesrovimab-cfor)
Pulmonary conditions	<ul style="list-style-type: none"> ● Exdensur (depemokimab-ulaa) 	<ul style="list-style-type: none"> ● Jascayd (nerandomilast) ● Brinsupri (brensocatib)
Oncologic Conditions	<ul style="list-style-type: none"> ● Datroway (datopotamab deruxtecán-dlnk), ● Emrelis (telisotuzumab vedotin-tllv) ● Ibtrozi (taletrectinib) ● Zegfrovy (sunvozertinib) ● Hyrnuo (sevabertinib) ● Hernexeos 	<ul style="list-style-type: none"> ● Gomekli (mirdametinib) ● Romvimza (vimseltinib) ● Avmapki Fakzynja Co-Pack (avutometinib + defactinib) ● Lynozytic (linvoseltamab-gcpt) ● enpulimab-kcqx (penpulimab-kcqx) ● Inluriyo (imlunestrant)

	<ul style="list-style-type: none"> (zongertinib) • Komzifti (ziftomenib) • Modeyso (dordaviprone) • Grafapex (treosulfan) 	<ul style="list-style-type: none"> • Keytruda Qlex (pembrolizumab + berahyaluronidase alfa-pmph)
Cardiovascular Conditions	<ul style="list-style-type: none"> • Myqorzo (aficamten) 	<ul style="list-style-type: none"> • Cardamyst (etripamil)
Endocrine/ Metabolic Conditions	<ul style="list-style-type: none"> • Lerochol (lerodalcibep-liga) • Redemplo (plozasiran) 	<ul style="list-style-type: none"> • Sephience (sepiapterin) • Forzinity (elamipretide) • Palsonify (paltusotine)
Renal Conditions	<ul style="list-style-type: none"> • Vanrafia (atrasentan) 	<ul style="list-style-type: none"> • Voyxact (sibeprenlimab-szsi)
Immunologic/ Hematologic Conditions	<ul style="list-style-type: none"> • Andembry (garadacimab-gxii) • Dawnzera (donidalorsen) • Ekterly (sebetralstat) • Imaavy (nipocalimab-aahu) 	<ul style="list-style-type: none"> • Wayrilz (rilzabrutinib) • Qfitlia (fitusiran) • Yartemlea (narsoplimab-wuug)
Neurologic/Pain/ Neuromuscular Disorders	<ul style="list-style-type: none"> • Journavx (suzetrigine) 	<ul style="list-style-type: none"> • Kygevvi (doxecitine + doxribtimine)
Ophthalmologic Disorders	<ul style="list-style-type: none"> • Tryptyr (acoltremon) 	<ul style="list-style-type: none"> • Vizz (aceclidine)
Women's Health	<ul style="list-style-type: none"> • Lynkuet (elinzanetant) 	
Gastrointestinal Conditions	<ul style="list-style-type: none"> • Nereus (tradipitant) 	
Dermatology Conditions	<ul style="list-style-type: none"> • Rhapsido (remibrutinib) 	<ul style="list-style-type: none"> • Anzupgo (delgocitinib)

References:

1. FDA. Novel drug approvals for 2025 [Internet]. U.S. Department of Health & Human Services. Silver Spring, MD. U.S. Food and Drug Administration. 2026 Jan 2 [cited 2026 Jan 18]. Available from: <https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025>
2. UpToDate Lexidrug (UpToDate) [AUHCOP Intranet]. Waltham, MA. UpToDate Inc. [updated 2026, accessed 2026 Jan 18]. [about 2 p.]. Available from: <https://online.lexi.com/lco/action/home>
3. FDA. New drug therapy approval 2025 [Internet]. U.S. Department of Health & Human Services. Silver Spring, MD. U.S. Food and Drug Administration. 2026 Jan 23 [cited 2026 Jan 25]. Available from: <https://www.fda.gov/media/190705/download?attachment>



The last “dose” ...

“Medicine is a science of uncertainty and an art of probability.”

-Sir William Osler - 1849 to 1919 [A Canadian physician and one of the founding professors of Johns Hopkins Hospital. He created the first residency program for the specialty training of physicians]

Health Professional with a Question? Drugs – Therapeutics – Pharmacy Practice?

Please contact us. We can help resolve your issue.

Please call **344-844-4400** Monday-Friday 8:00 to 5:00 pm (some holidays excepted)
or visit our website, 24/7 at: <http://pharmacy.auburn.edu/di/>

*An electronic bulletin of drug and health-related news highlights, a service of ...
Auburn University, Harrison School of Pharmacy, Drug Information Center
• Phone 334-844-4400 • <http://pharmacy.auburn.edu/di/>
Bernie R. Olin, Pharm.D., Director
Archived issues are available at: <http://pharmacy.auburn.edu/di/auinformed.php>*